NCT00986531View on ClinicalTrials.gov

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Schizophrenia
Interventions
DRUG

AZD8529

2 capsules by mouth for 3 days

DRUG

Placebo to match AZD8529

2 capsules by mouth for 3 days

Trial Locations (1)

Unknown

Research Site, Philadelphia

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY